Filing Flows › Viridian Therapeutics (VRDN) › Guidance & outlook
Viridian Therapeutics (VRDN) guidance and outlook
Viridian Therapeutics' 10-Q filed Nov 4, 2026 makes 22 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 4, 2026
- We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience.
- We aim to develop differentiated, potential best-in-class medicines that could lead to improved patient outcomes, reduced side effects, improved quality of life, and expanded market access.
- Our portfolio targets validated pathways and disease-driving mechanisms in autoimmune and rare diseases.
- Following approval, we launched veligrotug in the United States under the trade name Lumvoa with commercial launch efforts focused on reaching target prescribers, enabling reliable access for patients, supporting physician offices and infusion centers, and engaging effectively with payors.
- We anticipate submitting a BLA for elegrobart in the first quarter of 2027.
- We enrolled 321 patients in this safety study, exceeding the target enrollment of 284 patients due to demand, and achieved primary study completion in April 2026.
- We enrolled 87 patients in the autoinjector study, exceeding the target enrollment of 75 patients, and completed the study in May 2026.
- Our multi-pronged engineering approach has resulted in a portfolio of FcRn-targeting molecules that leverage the clinically and commercially validated mechanism of FcRn inhibition while potentially addressing the limitations of current agents such as incomplete immunoglobulin G (“IgG”) suppression, safety, and inconvenience of dosing.
- We expect to communicate development plans for our portfolio of FcRn inhibitors in the fourth quarter of 2026.
- We expect to initiate a phase 1 clinical trial of our anti-TSHR antibody, VRDN-292, starting in patients with Graves’ disease in the fourth quarter of 2026.
- In the future, we expect to continue to generate revenue from a combination of license fees and other upfront payments, payments for research and development services, milestone payments, product sales, and royalties in connection with strategic alliances and from customers.
- We expect that any revenue we generate could fluctuate from quarter to quarter as a result of the timing of our achievement of development and commercial milestones, the timing and amount of payments relating to such milestones and the extent to which any of our product candidates are approved and successfully commercialized by us or our strategic alliance collaborators, if any.
Viridian Therapeutics' latest quarter
Viridian Therapeutics, Q3 2026: revenue $25.8M (-64% year over year), operating margin -401.8%, net loss $101M, operating cash flow −$92.8M. The chart follows the revenue to costs, profit and cash.
Questions
What does Viridian Therapeutics expect?
We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience. We aim to develop differentiated, potential best-in-class medicines that could lead to improved patient outcomes, reduced side effects, improved quality of life, and expanded market access. Our portfolio targets validated pathways and disease-driving mechanisms in autoimmune and rare diseases.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.